The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin
Open accessAbstract
BackgroundIn patients with end-stage renal dis- ease, anemia develops as a result of erythropoietin deficiency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially.We examined the risks and benefits of normalizing the hematocrit in patients with cardiac disease who were undergoing hemodialysis. MethodsWe studied 1233 patients with clinical ev- idence of congestive heart failure or ischemic heart disease who were undergoing hemodialysis: 618 patients were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 percent, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percent throughout the study.The median duration of treatment was 14 months.The primary end point was the length of time to death or a first nonfatal myocardial infarction. ResultsAfter 29 months, there were 183 deaths and 19 first nonfatal myocardial infarctions among the patients in the normal-hematocrit group and 150 deaths and 14 nonfatal myocardial infarctions among those in the low-hematocrit group (risk ratio for the normal-hematocrit group as compared with the lowhematocrit group, 1.3; 95 percent confidence interval, 0.9 to 1.9).Although the difference in event-free survival between the two groups did not reach the prespecified statistical stopping boundary, the study was halted.The causes of death in the two groups were similar.The mortality rates decreased with increasing hematocrit values in both groups.The patients in the normal-hematocrit group had a decline in the adequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit group. ConclusionsIn patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended.(N
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The acute hemodynamic responses of EPO administration may result in impaired perfusion/oxygen supply to the tissues and contribute to acute adverse events such as enhanced PLT aggregation, thromboembolism, and myocardial ischemia (17, 45).”
From Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia (2017) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Salonen, J. T., Nyyssönen, K., Korpela, H., Tuomilehto, J., Seppänen, R., & Salonen, R. (1992) · Circulation · doi:10.1161/01.cir.86.3.803 · Cited by 1,284
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citationImpact of left ventricular hypertrophy on survival in end-stage renal disease
Silberberg, J. S., Barré, P. E., Prichard, S. S., & Sniderman, A. D. (1989) · Kidney International · doi:10.1038/ki.1989.192 · Cited by 780
The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin
Evans, R. W. (1990) · JAMA · doi:10.1001/jama.263.6.825 · Cited by 401
Research works printed but not linked: 8
- Pascual J, 1991, Clin Nephrol, 35, 280
- Eschbach JW, 1993, J Am Soc Nephrol, 4, 425
- Collins A, 1994, J Am Soc Nephrol, 5, 439
- Nissenson AR, 1996, J Am Soc Nephrol, 7, 1459
- Barany P, 1996, J Am Soc Nephrol, 7, 1472
- Benz RL, 1996, J Am Soc Nephrol, 7, 1473
- Hoen B, 1995, Nephrol Dial Transplant, 10, 377
- Collins A, 1997, J Am Soc Nephrol, 8, 190A
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Warady, B. A., Barcia, J. P., Benador, N. M., Jankauskienė, A., Olson, K. A., Podracká, Ľ., Shavkin, A., Srivaths, P. R., Wong, C. J., & Petersen, J. (2017) · Pediatric Nephrology · doi:10.1007/s00467-017-3758-5 · Cited by 13
The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease
Bazeley, J. W., & Wish, J. B. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.06.001 · Cited by 13
Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients
Kshirsagar, A. V., & Li, X. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.05.001 · Cited by 13
Kim, I., Lee, B. K., Yang, P., Joung, B., & Kim, J. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa071 · Cited by 13
The ASCEND-ND trial: study design and participant characteristics
Perkovic, V., Blackorby, A., Čižman, B., Carroll, K., Cobitz, A. R., Davies, R., Dimino, T. L., Jha, V., Johansen, K. L., Lópes, R. D., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab318 · Cited by 13
Zheng, X., Chen, X., Liu, T., Jiang, J., Cui, X., Zhao, Q., & Hu, P. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123274 · Cited by 13
Anemia in Chronic Renal Disease
Greenbaum, L. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-11665-0_59 · Cited by 13
Locatelli, F., & Vecchio, L. D. (2023) · Kidney International · doi:10.1016/j.kint.2023.03.026 · Cited by 13
The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients
Yahiro, M., Kuragano, T., Kida, A., Kitamura, R., Furuta, M., Hasuike, Y., Otaki, Y., Nonoguchi, H., & Nakanishi, T. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-011-0584-0 · Cited by 13
Hemoglobin Control, ESA Resistance, and Regular Low‐Dose IV Iron Therapy: A Review of the Evidence
Singh, A. K. (2008) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2008.00518.x · Cited by 13
Ishigami, J., Onishi, T., Shikuma, S., Akita, W., Mori, Y., Asai, T., Kuwahara, M., Sasaki, S., & Tsukamoto, Y. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0659-6 · Cited by 13
Hatamizadeh, P., Ravel, V., Lukowsky, L. R., Molnar, M. Z., Moradi, H., Harley, K., Pahl, M. V., Kovesdy, C. P., & Kalantar‐Zadeh, K. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft411 · Cited by 13
Erythropoiesis-Stimulating Agent Use After Changes in Medicare Reimbursement Policies
Hershman, D. L., Neugut, A. I., Shim, J., Glied, S., Tsai, W., & Wright, J. D. (2014) · Journal of Oncology Practice · doi:10.1200/jop.2013.001255 · Cited by 13
The Design of Randomized Controlled Trials
Curtis, B. M., Barrett, B. J., & Parfrey, P. S. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-385-1_5 · Cited by 13
Association of Pre-End-Stage Renal Disease Hemoglobin with Early Dialysis Outcomes
Kleine, C., Soohoo, M., Ranasinghe, O. N., Park, C., Marroquin, M., Obi, Y., Rhee, C. M., Moradi, H., Kovesdy, C. P., Kalantar‐Zadeh, K., et al. (2018) · American Journal of Nephrology · doi:10.1159/000489223 · Cited by 13
Wetmore, J. B., Li, S., Yan, H., Xu, H., Peng, Y., Sinsakul, M. V., Liu, J., & Gilbertson, D. T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203767 · Cited by 13
Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives
de Vries, J. K., Levin, A., Loud, F. C., Adler, A., Mayer, G. J., & Pena, M. J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13412 · Cited by 13
Levi, A., Simard, T., & Glover, C. A. (2020) · Seminars in Dialysis · doi:10.1111/sdi.12886 · Cited by 13
Gupta, S., Sage, A. M., & Singh, A. K. (2005) · Analytica Chimica Acta · doi:10.1016/j.aca.2005.07.065 · Cited by 13
Amann, K., Hofstetter, J., Câmpean, V., Koch, A., Groß, M.-L., Veelken, R. A., & Ritz, E. (2006) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-006-0219-0 · Cited by 13
Congestive heart failure-related anemia and a role for erythropoietin
Akram, K., & Pearlman, B. L. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.05.071 · Cited by 13
Broken pump or leaky filter? Renal dysfunction in heart failure a contemporary review
Petrie, C. J., Mark, P. B., & Weir, R. A. P. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.12.016 · Cited by 13
Hayashi, M. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.suppl_9.8 · Cited by 13
Tanaka, Y., Joki, N., & Hase, H. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm266 · Cited by 13
Spiegel, D. M. (2006) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2006.00171.x · Cited by 13
Singh, A. K. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010020178 · Cited by 13
Grigorian-Shamagian, L., Roman, A. V., Mazón‐Ramos, P., Pedreira-Pérez, M., Rigueiro‐Veloso, P., & González‐Juanatey, J. R. (2005) · Medicina Clínica · doi:10.1157/13081371 · Cited by 13
Cardiac Disease in Chronic Kidney Disease: Current Understandings and Opportunities for Change
Levin, A. (2004) · Blood Purification · doi:10.1159/000074920 · Cited by 13
International treatment guidelines for anaemia in chronic kidney disease — what has changed?
MacGinley, R., & Walker, R. G. (2013) · The Medical Journal of Australia · doi:10.5694/mja13.10538 · Cited by 13
Anemia in Non–Dialysis-Dependent CKD: To Treat or Not to Treat?
Fishbane, S. N., Ross, D. W., & Hong, S. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.11.006 · Cited by 13
Eryptosis in renal anemia: mechanisms, clinical implications, and therapeutic targeting
Deng, X., Gong, X., Huang, Y., Zhou, J., & Ren, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1718803 · Cited by 12
Dai, S., Chen, Y., Hao, C., Ge, X., Xie, Q., Shang, D., & Zhu, T. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13696 · Cited by 12
Usage of the Anemia Control Model Is Associated with Reduced Hospitalization Risk in Hemodialysis
Garbelli, M., Salvador, M. E. B., Bello, A. R., Toro, D. S., Bellocchio, F., Fumagalli, L., Chermisi, M., Apel, C., Petrovic, J., Kendzia, D., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12102219 · Cited by 12
Araji, G., Keesari, P. R., Chowdhry, V. K., Valsechi-Diaz, J., Afif, S., Diab, W., & El‐Sayegh, S. (2024) · World Journal of Nephrology · doi:10.5527/wjn.v13.i4.100268 · Cited by 12
Update on erythropoiesis-stimulating agents
Goodnough, L. T., & Shander, A. (2013) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2012.11.006 · Cited by 12
Evans, M., Carrero, J. J., Bellocco, R., Barany, P. F., Qureshi, A. R., Seeberger, A., Jacobson, S. H., Hylander-Rössner, B., Rotnitzky, A. G., & Sjölander, A. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw328 · Cited by 12
Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
McMahon, G. M., & Singh, A. K. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000554 · Cited by 12
Zhou, Q., Mao, M., Li, J., & Deng, F. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2195011 · Cited by 12
McMahon, L. P. (2008) · Nephrology · doi:10.1111/j.1440-1797.2008.00997.x · Cited by 12
Continuous Quality Improvement in Daily Clinical Practice: A Proof of Concept Study
Lorch, J. A., & Pollak, V. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097066 · Cited by 12
Stein, A., Mohr, F., Laux, M., Thieme, S., Lorenz, B., Cetindis, M., Hackl, J., Groha, P., Demetz, G., Schulz, S., et al. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-08-0552 · Cited by 12
Optimal hemoglobin level for anemia treatment in a cohort of hemodialysis patients
Jung, M. Y., Hwang, S. Y., Hong, Y. A., Oh, S. Y., Seo, J. H., Lee, Y. M., Park, S., Kim, J. S., Wang, J. K., Kim, J. Y., et al. (2015) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2014.11.003 · Cited by 12
Cardiovascular diseases in kidney transplant recipients: the role of anemia
Kadambi, P. V., & Javaid, B. (2004) · Advances in Chronic Kidney Disease · doi:10.1053/j.arrt.2004.04.003 · Cited by 12
del Castillo, N., García-García, P., Rivero, A., Jiménez, A., Macia, M. L., Getino, M. A., Méndez, M. L., García-Pérez, J., & Navarro‐González, J. F. (2012) · BMC Nephrology · doi:10.1186/1471-2369-13-60 · Cited by 12
Locatelli, F., & Becker, H. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-s1-16 · Cited by 12
Fishbane, S., Roger, S. D., Martin, E. R., Runyan, G., O’Neil, J., Qiu, P., & Locatelli, F. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03440412 · Cited by 12
Kwon, O., Jang, H. M., Jung, H., Kim, Y. S., Kang, S., Yang, C. W., Kim, N., Choi, J., Cho, J., Kim, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140241 · Cited by 12
Yap, Y., Chuang, H., Wu, C., Chi, W., Lin, C.-H., & Liu, Y. (2016) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12383 · Cited by 12
The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease
Yarnoff, B., Hoerger, T. J., Simpson, S. A., Pavkov, M. E., Burrows, N. R., Shrestha, S. S., Williams, D. E., & Zhuo, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157323 · Cited by 12
Cardiovascular Aspects of Kidney Disease
Wheeler, D. C., Haynes, R., Landray, M., & Baigent, C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10055-7 · Cited by 12
Interdialytic Weight Gain Effects on Hemoglobin Concentration and Cardiovascular Events
Hara, T., Kimachi, M., Akizawa, T., Fukuhara, S., & Yamamoto, Y. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.07.027 · Cited by 12
Murea, M., Deira, J., Kalantar‐Zadeh, K., Casino, F. G., & Basile, C. (2021) · Seminars in Dialysis · doi:10.1111/sdi.13027 · Cited by 12
The Effect of Hemoglobin Level on Arteriovenous Fistula Survival in Iranian Hemodialysis Patients
Zadeh, M. K., Gholipour, F., & Hadipour, R. (2008) · The Journal of Vascular Access · doi:10.1177/112972980800900210 · Cited by 12
EPO or PlacEPO? Science versus Practical Experience
Hardeman, M. R., Alexy, T., Brouwer, B., Connes, P., Jung, F., Kuipers, H., & Baskurt, O. K. (2014) · Biorheology · doi:10.3233/bir-140655 · Cited by 12
Tefferi, A. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1316 · Cited by 12
Therapeutic potential of erythropoietin in cardiovascular disease: Erythropoiesis and beyond
Westenbrink, B. D., Voors, A. A., Ruifrok, W.-P. T., van Gilst, W. H., & van Veldhuisen, D. J. (2007) · Current Heart Failure Reports · doi:10.1007/s11897-007-0030-5 · Cited by 12
Treating Pain to Improve Quality of Life in End‐Stage Renal Disease
Patel, S. S. (2013) · Seminars in Dialysis · doi:10.1111/sdi.12066 · Cited by 12
Chen, L., Ling, Y., Lin, C., He, J., & Guan, T. (2015) · Frontiers in Public Health · doi:10.3389/fpubh.2015.00258 · Cited by 12
Vullaganti, S., Goldsmith, J., Teruya, S. L., Alvarez, J., Helmke, S. T., & Maurer, M. S. (2014) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1671-5411.2014.02.002 · Cited by 12
Mineral and bone disorders in conventional hemodialysis: Challenges and solutions
Hamano, T. (2018) · Seminars in Dialysis · doi:10.1111/sdi.12729 · Cited by 12
Vascular Complications after Kidney Transplantation
Allen, R. D. M. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3343-1.50030-x · Cited by 12
Risks and Benefits of Erythropoiesis-Stimulating Agents in Cancer Management
Beutel, G., & Ganser, A. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.04.004 · Cited by 12
Foley, R. N., & Agarwal, R. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00337.x · Cited by 12
Coyne, D. W. (2008) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2008.00423.x · Cited by 12
Murphy, S. W. (2003) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2003.16033.x · Cited by 12
Hypothesis Versus Association: The Optimal Hemoglobin Target Debate
Strippoli, G. F., & Craig, J. C. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.09.009 · Cited by 12
Endotoxaemia in Haemodialysis: A Novel Factor in Erythropoetin Resistance?
Harrison, L. E. A., Burton, J. O., Szeto, C., Li, P. K., & McIntyre, C. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040209 · Cited by 11
Cancer Chemoprevention—the Cardiovascular Model
Temple, R. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0049 · Cited by 11
Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study
Peters, N. O., Jay, N., Cridlig, J., Rostoker, G., & Frimat, L. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0513-x · Cited by 11
Rodrigues, A. T., Colugnati, F. A. B., & Bastos, M. G. (2018) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2017-0014 · Cited by 11
Musio, F. M. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1830371 · Cited by 11
Tanaka, K., Fujiwara, M., Saito, H., Iwasaki, T., Oda, A., Watanabe, S., Kanno, M., Kimura, H., Tani, Y., Asai, J., et al. (2021) · Renal Replacement Therapy · doi:10.1186/s41100-021-00332-0 · Cited by 11
Challenging patient phenotypes in the management of anaemia of chronic kidney disease
Pramod, S., & Goldfarb, D. S. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14681 · Cited by 11
Singh, N. S., Johnson, R. J., Matheson, M. B., Carlson, J. M., Hooper, S. R., & Warady, B. A. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05682-3 · Cited by 11
Hemoglobin and Clinical Outcomes in Hemodialysis: An Analysis of US Medicare Data From 2018 to 2020
Young, E. W., Wang, D., Kapke, A., Pearson, J., Turenne, M. N., Robinson, B. M., & Huff, E. D. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100578 · Cited by 11
Hassan, S., Mumford, L. L., Robinson, S. J., Foukanelli, D., Torpey, N., Ploeg, R. J., Mamode, N., Murphy, M. F., Brown, C. J., Roberts, D. J., et al. (2023) · Frontiers in Nephrology · doi:10.3389/fneph.2023.1236520 · Cited by 11
Haemoglobin trajectories in chronic kidney disease and risk of major adverse cardiovascular events
Gall, L. L., Harambat, J., Combe, C., Philipps, V., Proust‐Lima, C., Dussartre, M., Drüeke, T. B., Choukroun, G. J., Fouque, D. P., Frimat, L., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad235 · Cited by 11
Early versus delayed erythropoietin for the anaemia of end-stage kidney disease
Daza, J. A. C., Martí-Carvajal, A. J., García, A. A., Rodelo-Ceballos, J. R., González, N. Y., Páez-Canro, C., Munarriz, C. A. L., & Urrútia, G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011122.pub2 · Cited by 11
Hirth, R. A., Turenne, M. N., Wheeler, J. R. C., Ma, Y., & Messana, J. M. (2010) · Medical Care · doi:10.1097/mlr.0b013e3181e3570a · Cited by 11
Management of Cardiovascular Disease in the Renal Transplant Recipient
Rigatto, C. (2005) · Cardiology Clinics · doi:10.1016/j.ccl.2005.03.008 · Cited by 11
Andrews, D. A., Pyrah, I. T. G., Boren, B. M., Tannehill‐Gregg, S. H., & Lightfoot-Dunn, R. M. (2013) · Toxicologic Pathology · doi:10.1177/0192623313486317 · Cited by 11
Maoujoud, O., Ahid, S., & Cherrah, Y. (2016) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s96027 · Cited by 11
Tonelli, M. A., Klarenbach, S. W., Wiebe, N., Shrive, F. M., Hemmelgarn, B. R., & Manns, B. (2008) · Cited by 11
Patient-Centred Outcomes in Anaemia and Renal Disease: A Systematic Review
Staibano, P., Perelman, I., Lombardi, J., Davis, A., Tinmouth, A. T., Carrier, M., Stevenson, C., & Saidenberg, E. (2019) · Kidney Diseases · doi:10.1159/000502208 · Cited by 11
Kidney dysfunction requiring dialysis is a heterogeneous syndrome: we should treat it like one
Murea, M., Flythe, J. E., Anjay, R., Emaad, A.-R. M., Gupta, N., Kovach, C., Vachharajani, T. J., Kalantar‐Zadeh, K., Casino, F. G., & Basile, C. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000754 · Cited by 11
Park, H., Desai, R. A., Liu, X., Smith, S. M., Hincapie‐Castillo, J. M., Henry, L. L., Goodin, A. J., Gopal, S., Pepine, C. J., & Mohandas, R. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14361121 · Cited by 11
Anemia da Doença Renal Crónica: O Estado da Arte
Farinha, A., Nunes, A. R., Mairos, J. S., & Fonseca, C. (2022) · Acta Médica Portuguesa · doi:10.20344/amp.17284 · Cited by 11
Fujii, H., Hamano, T., Tsuchiya, K., Kuragano, T., Joki, N., Tsuruya, K., Honda, H., Uemura, Y., & Nitta, K. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.12.051 · Cited by 11
Badve, S. V., Hawley, C. M., & Johnson, D. W. (2010) · Nephrology · doi:10.1111/j.1440-1797.2010.01407.x · Cited by 11
BPCO et érythropoïèse : interactions et conséquences
Chambellan, A., Coulon, S., Cavailles, A., Hermine, O., & Similowski, T. (2012) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2011.12.004 · Cited by 11
Anaemia of chronic kidney disease
Macdougall, I. C. (2007) · Medicine · doi:10.1016/j.mpmed.2007.05.008 · Cited by 11
Hayashi, T., Kimura, T., Yasuda, K., Obi, Y., Sasaki, K., Iio, K., Miyasato, K., Kamimura, T., Kitamura, H., Tsubakihara, Y., et al. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0705-4 · Cited by 11
Capelli, J. P., & Kushner, H. (2008) · Hemodialysis International · doi:10.1111/j.1542-4758.2008.00309.x · Cited by 11
Clinical benefits of slowing the progression of renal failure
Locatelli, F., Vecchio, L. D., & Pozzoni, P. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09927.x · Cited by 11
Ruvinov, E., Sharabani‐Yosef, O., Nagler, A., Einbinder, T., Feinberg, M. S., Holbová, R., Douvdevani, A., & Leor, J. (2008) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-1-7 · Cited by 11
Sturm, G., Lamina, C., Zitt, E., Lhotta, K., Lins, F., Freistätter, O., Neyer, U., & Kronenberg, F. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq101 · Cited by 11
Anemia and cardiovascular and kidney disease
Jurkovitz, C. T., Abramson, J. L., & McClellan, W. M. (2006) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000214769.11609.2d · Cited by 11
TARGT Gene Therapy Platform for Correction of Anemia in End-Stage Renal Disease
Blum, S., Shapir, N., Miari, R., Lerner, B., Koren, B., Doenyas‐Barak, K., Efrati, S., Pérgola, P. E., Schwartz, D., Chernin, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1606202 · Cited by 11
Chronic kidney disease-associated cardiovascular disease: scope and limitations of animal models
Sadeghi‐Alavijeh, O., Tadayyon, M., & Caplin, B. (2017) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000132 · Cited by 11
Anemia in Chronic Kidney Disease
Coyne, D. W. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.13305 · Cited by 11
Metadata
- Authors
- Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A.
- Affiliations
- Henry Ford Hospital (US)
- University of Virginia Health System (US)
- Amgen (United States) (US)
- University of California, Los Angeles (US)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-08-27
- Volume
- 339
- Issue
- 9
- Pages
- 584-590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2331665138
- Cited by
- 1,930
- References
- 28
- Citations by year
- 2026: 23 · 2025: 33 · 2024: 36 · 2023: 44 · 2022: 52 · 2021: 82 · 2020: 59 · 2019: 61 · 2018: 59 · 2017: 68 · 2016: 75 · 2015: 56 · 2014: 89 · 2013: 102 · 2012: 99
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hematocrit, recombinant human erythropoietin, epoetin, hemodialysis, end-stage renal disease, anemia, congestive heart failure, ischemic heart disease, myocardial infarction, mortality, dialysis adequacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
